{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:36:14Z","timestamp":1787960174958,"version":"build-2784847793"},"update-to":[{"DOI":"10.1002\/14651858.cd005019.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T00:00:00Z","timestamp":1390780800000}}],"reference-count":190,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd005019.pub4","type":"journal-article","created":{"date-parts":[[2014,1,27]],"date-time":"2014-01-27T23:33:53Z","timestamp":1390865633000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["HMG CoA reductase inhibitors (statins) for kidney transplant recipients"],"prefix":"10.1002","volume":"2015","author":[{"given":"Suetonia C","family":"Palmer","sequence":"first","affiliation":[{"name":"University of Otago Christchurch; Department of Medicine; 2 Riccarton Ave PO Box 4345 Christchurch New Zealand 8140"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sankar D","family":"Navaneethan","sequence":"additional","affiliation":[{"name":"Glickman Urological and Kidney Institute, Cleveland Clinic; Department of Nephrology and Hypertension; Cleveland OH USA 44195"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlado","family":"Perkovic","sequence":"additional","affiliation":[{"name":"The George Institute for International Health; Renal and Metabolic Division; Camperdown NSW Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Johnson","sequence":"additional","affiliation":[{"name":"Princess Alexandra Hospital; Department of Nephrology; Ipswich Rd Woolloongabba Queensland Australia 4102"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagar U","family":"Nigwekar","sequence":"additional","affiliation":[{"name":"Harvard Medical School; Brigham and Women's Hospital, Massachusetts General Hospital, Scholars in Clinical Sciences Program; Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Hegbrant","sequence":"additional","affiliation":[{"name":"Diaverum Renal Services Group; Medical Office; PO Box 4167 Lund Sweden SE-227 22"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni FM","family":"Strippoli","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Renal Group, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"Mario Negri Sud Foundation; Clinical Pharmacology and Epidemiology; Santa Maria Imbaro Italy"},{"name":"Amedeo Avogadro University of Eastern Piedmont; Novara Italy"},{"name":"Diaverum; Medical Scientific Office; Lund Sweden"},{"name":"Diaverum Academy; Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,1,27]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/TP.0b013e31818bfce8","article-title":"Cerebrovascular events in renal transplant recipients","volume":"87","author":"Abedini","year":"2009","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.2215\/CJN.00930209","article-title":"Inflammation in renal transplantation","volume":"4","author":"Abedini","year":"2009","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005019.pub4-BIB0003|cit3","first-page":"207","article-title":"Association between body mass index (BMI) all cause mortality, renal and cardiac endpoints in renal transplant recipients in the Alert Extension Study [abstract no: 56]","volume":"9","author":"Abedini","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub4-BIB0004|cit4","first-page":"68A","article-title":"Asymmetric dimethylarginine (ADMA) predicts progression to graft failure and major cardiac events in renal transplant recipients (RTR) [abstract no: F-FC149]","volume":"17","author":"Abedini","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/ki.2009.382","article-title":"Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortality in renal transplant recipients","volume":"77","author":"Abedini","year":"2010","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1399-0012.2006.00555.x","article-title":"No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study","volume":"20","author":"Fellstrom","year":"2006","journal-title":"Clinical Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub4-BIB0007|cit7","first-page":"187A","article-title":"Renal transplant function as a risk factor for graft loss, cardiac disease and all cause mortality in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub4-BIB0008|cit8","first-page":"10A","article-title":"Effects of fluvastatin on graft losses and renal function in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub4-BIB0009|cit9","first-page":"185A","article-title":"Risk factors for graft loss or doubling of serum creatinine in renal transplantation - experience from the ALERT trial [abstract]","volume":"14","author":"Fellstrom","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub4-BIB0010|cit10","first-page":"236","article-title":"Effects of fluvastatin on renal transplant function and graft loss in renal transplant patients in ALERT (Assessment of LEscol in Renal Transplantation) [abstract no: M736]","volume":"18","author":"Fellstrom","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstrom","year":"2004","journal-title":"Kidney International"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.TP.0000147338.34323.12","article-title":"Risk factors for reaching renal endpoints in the assessment of Lescol in renal transplantation (ALERT) trial","volume":"79","author":"Fellstrom","year":"2005","journal-title":"Transplantation"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00007890-200407271-00161","article-title":"Renal transplant function as a risk factor for cardiovascular disease and mortality and for all cause mortality in renal transplantation - experience from the ALERT trial [abstract]","volume":"78","author":"Fellstrom","year":"2004","journal-title":"Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1097\/01.TP.0000160764.35083.B8","article-title":"Renal dysfunction as a risk factor for mortality and cardiovascular disease in renal transplantation: experience from the Assessment of Lescol in Renal Transplantation trial","volume":"79","author":"Fellstrom","year":"2005","journal-title":"Transplantation"},{"issue":"8","key":"10.1002\/14651858.CD005019.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1111\/j.1600-6143.2005.00983.x","article-title":"Renal dysfunction is a strong and independent risk factor for mortality and cardiovascular complications in renal transplantation","volume":"5","author":"Fellstrom","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD005019.pub4-BIB0016|cit16","first-page":"261","article-title":"Influence of renal transplant function on cardiovascular disease and all cause mortality in the ALERT trial [abstract no: 375]","volume":"4","author":"Fellstrom","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub4-BIB0017|cit17","first-page":"19A","article-title":"Parathyroid hormone and phosphate - risk factors for post-transplant cardiovascular disease? [abstract no: TH-FC084]","volume":"17","author":"Holdaas","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0018|cit18","first-page":"894A","article-title":"Statins endothelial function in renal transplant recipients - a randomised single centre study [abstract no: A4677]","volume":"12","author":"Holdaas","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1002\/14651858.CD005019.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/174182670100800202","article-title":"Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data","volume":"8","author":"Holdaas","year":"2001","journal-title":"Journal of Cardiovascular Risk"},{"issue":"Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0021|cit21","first-page":"A88","article-title":"Long term effectiveness and safety of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: M-PO50032]","volume":"10","author":"Holdaas","year":"2005","journal-title":"Nephrology"},{"issue":"Suppl 11","key":"10.1002\/14651858.CD005019.pub4-BIB0022|cit22","first-page":"328","article-title":"Risk factors for late new-onset diabetes mellitus after renal transplantation [abstract no: 675]","volume":"5","author":"Holdaas","year":"2005","journal-title":"American Journal of Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub4-BIB0023|cit23","first-page":"185A","article-title":"Lipid-lowering therapy should be started early in the post-transplant period [abstract no: F-PO569]","volume":"14","author":"Holdaas","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005019.pub4-BIB0024|cit24","first-page":"v3","article-title":"Long term efficacy, safety and tolerability of fluvastatin in renal transplant recipients: the ALERT trial follow-up [abstract no: SO01]","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub4-BIB0025|cit25","first-page":"881A","article-title":"No detrimental effect of fluvastatin on renal function in diabetic renal transplant patients [abstract no: PUB561]","volume":"15","author":"Holdaas","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub4-BIB0026|cit26","first-page":"527A","article-title":"Prevalence and consequences of metabolic syndrome in a renal transplant population [abstract no: SA-PO1048]","volume":"15","author":"Holdaas","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD005019.pub4-BIB0027|cit27","first-page":"442","article-title":"Randomized double blind trial of fluvastatin for hypercholesterolemia in renal transplant recipients [abstract]","volume":"3","author":"Holdaas","year":"2003","journal-title":"American Journal of Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub4-BIB0028|cit28","first-page":"237","article-title":"Effects of fluvastatin on cardiovascular events in renal transplant patients: ALERT (Assessment LEscol in Renal Transplantation) [abstract]","volume":"18","author":"Holdaas","year":"2003","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0029|cit29","first-page":"72A","article-title":"Long term cardiac outcomes in renal transplant recipients receiving fluvastatin: The ALERT Extension Study [abstract]","volume":"16","author":"Holdaas","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00007890-200407271-00873","article-title":"No detrimental effect on renal function during long-term use of fluvastatin [abstract]","volume":"78","author":"Holdaas","year":"2004","journal-title":"Transplantation"},{"issue":"Nov","key":"10.1002\/14651858.CD005019.pub4-BIB0031|cit31","first-page":"662A","article-title":"Lipids as risk factors for cardiac events after renal transplantation - experience from the ALERT trial [abstract no: SU-PO590]","volume":"14","author":"Holdaas","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9374","key":"10.1002\/14651858.CD005019.pub4-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/ndt\/gfh735","article-title":"Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation","volume":"20","author":"Holdaas","year":"2005","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD005019.pub4-BIB0034|cit34","first-page":"443A","article-title":"Impact of hemoglobin levels on graft function, cardiac events and all-cause mortality after renal transplantation [abstract no: F-PO1502]","volume":"19","author":"Holdaas","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0035|cit35","unstructured":"Holdaas H Jardine A Holme I Brekke IB Wheeler DC Ostraat O A randomised controlled trial assessing the effect of fluvastatin on acute rejection rate following renal transplantation [abstract no: P0582W] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy) 2000"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0036|cit36","doi-asserted-by":"crossref","unstructured":"Holdaas H Jardine AG Wheeler DC Brekke IB Conlon PJ Fellstrom B Effect of fluvastatin on acute renal allograft rejection: a randomized multicenter trial Kidney International 2001 1990 7 21561172","DOI":"10.1046\/j.1523-1755.2001.00010.x"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.atherosclerosis.2009.06.020","article-title":"Comparison of predictive ability of lipoprotein components to that of traditional risk factors of coronary events in renal transplant recipients","volume":"208","author":"Holme","year":"2010","journal-title":"Atherosclerosis"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub4-BIB0038|cit38","first-page":"231A","article-title":"Osteoprotegerin - a novel risk factor post-transplant cardiovascular disease [abstract no: TH-PO581]","volume":"17","author":"Jardine","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD005019.pub4-BIB0039|cit39","first-page":"746A","article-title":"New targets for cardiovascular risk reduction in renal transplant recipients: post-hoc analyses of the ALERT study [abstract no: SU-PO991]","volume":"15","author":"Jardine","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1053\/j.ajkd.2005.05.014","article-title":"Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study","volume":"46","author":"Jardine","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study","volume":"4","author":"Jardine","year":"2004","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0042|cit42","first-page":"64A","article-title":"Pulse pressure and outcomes following renal transplantation [abstract no: SU-FC294]","volume":"14","author":"Jardine","year":"2003","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD005019.pub4-BIB0043|cit43","first-page":"488","article-title":"Adverse impact of steroids on outcome in the ALERT study [abstract]","volume":"4","author":"Jardine","year":"2004","journal-title":"American Journal of Transplantation"},{"issue":"Abstracts","key":"10.1002\/14651858.CD005019.pub4-BIB0044|cit44","first-page":"438A","article-title":"C-Reactive protein (CRP) and interleukin-6 (IL-6) are associated with long-term renal and cardiac outcomes in renal transplant recipients [abstract no: SA-PO446]","volume":"18","author":"Norby","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.24379","article-title":"Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study","volume":"60","author":"Norby","year":"2009","journal-title":"Arthritis & Rheumatism"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1399-0012.2006.00496.x","article-title":"Gender-associated risk factors for cardiac end points and total mortality after renal transplantation: post hoc analysis of the ALERT study","volume":"20","author":"Oien","year":"2006","journal-title":"Clinical Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1194\/jlr.M700076-JLR200","article-title":"Genetic analysis of fluvastatin response and dyslipidemia in renal transplant recipients","volume":"48","author":"Singer","year":"2007","journal-title":"Journal of Lipid Research"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1399-0012.2009.01025.x","article-title":"Metabolic syndrome and cardiovascular risk in renal transplant recipients: effects of statin treatment","volume":"23","author":"Soveri","year":"2009","journal-title":"Clinical Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005019.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/01.tp.0000332125.35721.30","article-title":"Metabolic syndrome and cardiovascular disease risk in renal transplant recipients in the ALERT trial: effects of statin treatment [abstract no: 604]","volume":"86","author":"Soveri","year":"2008","journal-title":"Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005019.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/01.tp.0000332662.36069.47","article-title":"Metabolic syndrome and risk of renal graft loss in the ALERT Trial [abstract no: 119]","volume":"86","author":"Soveri","year":"2008","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000188088","article-title":"Low-dose simvastatin is a well-tolerated and efficacious cholesterol-lowering agent in ciclosporin-treated kidney transplant recipients: double-blind, randomized, placebo-controlled study in 40 patients","volume":"68","author":"Arnadottir","year":"1994","journal-title":"Nephron"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0052|cit52","first-page":"1061","article-title":"Low dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]","volume":"10","author":"Bill","year":"1995","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0053|cit53","first-page":"417","article-title":"Six-month treatment with low-dose lovastatin does not improve kidney allograft function","volume":"20","author":"Bill","year":"1995","journal-title":"Polish Journal of Immunology"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0054|cit54","first-page":"144","article-title":"The effect of hypolipidemia treatment on the function of kidney transplanted from cadavers","volume":"97","author":"Paczek","year":"1997","journal-title":"Polskie Archiwum Medycyny Wewnetznej"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0055|cit55","first-page":"65","article-title":"Non-immune factors in chronic rejection. Is there a role for hypolipemic drugs?","volume":"2","author":"Paczek","year":"1997","journal-title":"Annals of Transplantation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD005019.pub4-BIB0056|cit56","first-page":"S574","article-title":"Treatment with low-dose lovastatin does not improve kidney allograft function during 6-month observation [abstract]","volume":"3","author":"Paczek","year":"1997","journal-title":"Nephrology"},{"issue":"1 Pt 2","key":"10.1002\/14651858.CD005019.pub4-BIB0057|cit57","first-page":"1043","article-title":"HMGCoA reductase inhibitors lovastatin and simvastatin in the treatment of hypercholesterolemia after renal transplantation","volume":"25","author":"Castelao","year":"1993","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0041-1345(01)02836-6","article-title":"Lipid-lowering long-term effects of six different statins in hypercholesterolemic renal transplant patients under cyclosporine immunosuppression","volume":"34","author":"Martinez-Castelao","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1159\/000045544","article-title":"Which dosage of simvastatin in renal transplant patients?","volume":"84","author":"Celik","year":"2000","journal-title":"Nephron"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/S0041-1345(01)02813-5","article-title":"Effect of pravastatin treatment on the evolution of extracoronary atherosclerosis in renal transplant patients","volume":"34","author":"Cofan","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0041-1345(01)02814-7","article-title":"Pravastatin improves low-density lipoprotein oxidation in renal transplantation","volume":"34","author":"Cofan","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0062|cit62","first-page":"677A","article-title":"Effect of lipid lowering therapy on endothelial function in renal allograft recipients [abstract]","volume":"9","author":"Hausberg","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0063|cit63","first-page":"A282","article-title":"HMG-CoA-reductase inhibitors improve brachial artery flow-mediated vasodilation in renal transplant recipients [abstract]","volume":"14","author":"Hausberg","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1046\/j.1523-1755.2001.0590041473.x","article-title":"Effect of fluvastatin on endothelium-dependent brachial artery vasodilation in patients after renal transplantation","volume":"59","author":"Hausberg","year":"2001","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub4-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"577","DOI":"10.5414\/NHP33577","article-title":"Sustained beneficial effect of a therapy with the HMG-Co-A-reductase inhibitor fluvastatin on endothelial function in renal transplant recipients","volume":"33","author":"Kosch","year":"2004","journal-title":"Nieren-und Hochdruckkrankheiten"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0272-6386(03)00207-5","article-title":"Effect of a 3-year therapy with the 3-hydroxy-3-methylglutaryl coenzyme a reductase-inhibitor fluvastatin on endothelial function and distensibility of large arteries in hypercholesterolemic renal transplant recipient","volume":"41","author":"Kosch","year":"2003","journal-title":"American Journal of Kidney Diseases"},{"issue":"8 Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0068|cit67","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1097\/00007890-200004271-00429","article-title":"Effects of lipid reduction on acute renal allograft rejection [abstract no: 429]","volume":"69","author":"Kasiske","year":"2000","journal-title":"Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0067|cit68","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00007890-200107270-00009","article-title":"The effects of lipid-lowering agents on acute renal allograft rejection","volume":"72","author":"Kasiske","year":"2001","journal-title":"Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0069|cit69","first-page":"1017","article-title":"Pravastatin lowers natural killer cell cytotoxicity and decreases the incidence of early acute rejection episodes in renal transplant patients [abstract]","volume":"5","author":"Katznelson","year":"1994","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0070|cit70","unstructured":"Katznelson S Wilkinson AH Danovitch GM Wang XM Chia D Ozawa M The impact of pravastatin on the incidence of acute rejection after renal transplantation and on cellular immune function [abstract] 14th Annual Meeting American Society of Transplant Physicians (ASTP);1995 May 10-14; Chicago (USA) 1995"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1097\/00007890-199605270-00010","article-title":"The effect of pravastatin on acute rejection after kidney transplantation--a pilot study","volume":"61","author":"Katznelson","year":"1996","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1034\/j.1399-0012.1999.130613.x","article-title":"A double-blind placebo controlled trial of simvastatin for the treatment of dyslipidaemia in renal allograft recipients","volume":"13","author":"Lepre","year":"1999","journal-title":"Clinical Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub4-BIB0073|cit73","first-page":"637","article-title":"Low-dose simvastatin is safe in hyperlipidaemic renal transplant patients","volume":"8","author":"Martinez Hernandez","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0074|cit74","first-page":"869","article-title":"Low dose simvastatin (LS) is safe in hyperlipidemic transplant patients treated with CyA [abstract]","volume":"3","author":"Martinez-Hernandez","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/S0041-1345(98)00538-7","article-title":"Treatment of hypercholesterolemia with fluvastatin in kidney transplant patients","volume":"30","author":"Melchor","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0076|cit76","first-page":"693A","article-title":"Comparison of atorvastatin (ATV) with fluvastatin (FLV) in renal transplant patients with dyslipoproteinemia [abstract]","volume":"9","author":"Raiola","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0078|cit77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1093\/ndt\/16.1.141","article-title":"Efficacy and drug interactions of the new HMG-CoA reductase inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients","volume":"16","author":"Renders","year":"2001","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0077|cit78","first-page":"694A","article-title":"Cerivastatin and atorvastatin: efficacy, safety and drug-interaction of the new HMG-COA reductase inhibitors in renal transplant patients [abstract]","volume":"9","author":"Renders","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1034\/j.1399-0012.2001.150305.x","article-title":"Effect of lovastatin, an HMG CoA reductase inhibitor, on acute renal allograft rejection","volume":"15","author":"Sahu","year":"2001","journal-title":"Clinical Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0080|cit80","first-page":"A288","article-title":"Role of lovastatin in prevention of acute rejection episodes in renal transplant recipient [abstract]","volume":"14","author":"Sharma","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0081|cit81","unstructured":"Garcia V Bittar A Keitel E Neumann J Saitovitch D Santos A Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptors? [abstract no: 1441] A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey) 2001"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0082|cit82","unstructured":"Garcia V Bittar A Keitel E Neumann J Saitovitch D Santos A Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind, randomized placebo controlled study [abstract no: 1439] A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey) 2001"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0083|cit83","unstructured":"Santos AF Keitel E Bittar A Neumann J Saitovich D Seelig DC Is cyclosporin microemulsion increasing the lipid-lowering effect of simvastatin on kidney graft receptor? [abstract no: 3311] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0084|cit84","unstructured":"Santos AF Keitel E Bittar A Neumann J Saitovich D Seelig DC Is simvastatin able to reduce the plasma levels of fibrinogen in kidney graft receptors? A double-blind randomized placebo controlled study [abstract no:3367] XIXth International Congress of the Transplantation Society; 2002 Aug 25-30; Miami (FL) 2002"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0087|cit85","doi-asserted-by":"crossref","unstructured":"Santos AF Keitel E Bittar AE Neumann J Treatment of hyperlipidemia in renal transplant recipients with simvastatin: a double-blind, randomized, placebo-controlled study [abstract no: PO601] XVIII International Congress of the Transplantation Society; 2000 Aug 27-Sept 1; Rome (Italy) 2000","DOI":"10.1016\/S0041-1345(00)02382-4"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub4-BIB0085|cit86","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1016\/S0041-1345(02)03541-8","article-title":"Simvastatin effect on NK cells activity in vivo: a double-blind randomized, placebo-controlled study","volume":"34","author":"Santos","year":"2002","journal-title":"Transplantation Proceedings"},{"issue":"1-2","key":"10.1002\/14651858.CD005019.pub4-BIB0086|cit87","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0041-1345(00)02382-4","article-title":"Safety and efficacy of simvastatin for hyperlipidemia in renal transplant recipients: a double-blind, randomized, placebo-controlled study","volume":"33","author":"Santos","year":"2001","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/TP.0b013e318174428d","article-title":"Fluvastatin in the prevention of renal transplant vasculopathy: results of a prospective, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Seron","year":"2008","journal-title":"Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005019.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/01.tp.0000331351.21567.ce","article-title":"The effects of rosuvastatin on 51CR-EDTA measured glomerular filtration rate and urinary albumin excretion in non-diabetic renal transplant recipients [abstract no: 1386]","volume":"86","author":"Sharif","year":"2008","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1600-6143.2009.02644.x","article-title":"The effect of rosuvastatin on insulin sensitivity and pancreatic beta-cell function in nondiabetic renal transplant recipients","volume":"9","author":"Sharif","year":"2009","journal-title":"American Journal of Transplantation"},{"issue":"2S","key":"10.1002\/14651858.CD005019.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/01.tp.0000332133.10859.3a","article-title":"The effects of rosuvastatin on insulin sensitivity and secretion in non-diabetic renal transplant recipients [abstract no: 611]","volume":"86","author":"Sharif","year":"2008","journal-title":"Transplantation"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD005019.pub4-BIB0092|cit92","first-page":"208","article-title":"Influence of rosuvastatin on attenuation of the metabolic syndrome in non-diabetic renal transplant recipients [abstract no: 60]","volume":"9","author":"Sharif","year":"2009","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0093|cit93","first-page":"A92","article-title":"Rosuvastatin is associated with few improvements in components of the metabolic syndrome, with no change in insulin resistance, in renal transplant recipients","volume":"1","author":"Sharif","year":"2009","journal-title":"Journal of Diabetes"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1034\/j.1399-0012.2003.00063.x","article-title":"Fluvastatin reduces atherogenic lipids without any effect on native endothelial function early after kidney transplantation","volume":"17","author":"Asberg","year":"2003","journal-title":"Clinical Transplantation"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0095|cit95","first-page":"A319","article-title":"The SOLAR (Study Of Lescol in Acute Rejection) study: rationale and baseline data [abstract]","volume":"14","author":"Holdaas","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0096|cit96","unstructured":"Holdaas H Jardine A Wheeler D Fluvastatin (lescol) demonstrates significant lipid-lowering benefits without affecting rejection rates in renal transplant recipients, for the SOLAR study group [abstract no: 1212] A Transplant Odyssey; 2001 Aug 20-23; Istanbul (Turkey) 2001"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1046\/j.1523-1755.2001.00010.x","article-title":"Effect of fluvastatin on acute renal allograft rejection: A randomized multicenter trial","volume":"60","author":"Holdaas","year":"2001","journal-title":"Kidney International"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S0041-1345(00)00921-0","article-title":"Comparison of the effects of simvastatin and pravastatin on acute rejection episodes in renal transplant patients","volume":"32","author":"Tuncer","year":"2000","journal-title":"Transplantation Proceedings"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.ajkd.2004.11.015","article-title":"First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease","volume":"45","author":"Baigent","year":"2005","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0100|cit100","first-page":"437a","article-title":"Efficacy and safety of simvastatin and safety of low-dose aspirin among patients with chronic kidney disease: final results of the first UK-heart and renal protection (UK-HARP-I) study [abstract no: SA-P0841]","volume":"13","author":"Baigent","year":"2002","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0101|cit101","first-page":"A312","article-title":"Lovastatin (L) versus fluvastatin (F) in the treatment of hypercholesterolemic (HCH) renal transplant recipients (RTR) [abstract]","volume":"14","author":"Vergoulas","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0102|cit102","first-page":"83","article-title":"Effects of clofibrate on plasma lipids and high-density lipoprotein levels in renal allograft recipients","volume":"12","author":"Bagdade","year":"1979","journal-title":"Clinical Nephrology"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0103|cit103","unstructured":"Blechman-Krom I An interventional trial in established chronic renal allograft rejection www.clinicaltrials.gov\/ct2\/show\/NCT00005010"},{"issue":"Sept","key":"10.1002\/14651858.CD005019.pub4-BIB0104|cit104","first-page":"680A","article-title":"Cholesterol and triglyceride levels in sirolimus-treated renal transplant recipients [abstract no: A3577]","volume":"11","author":"Blum","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000013487","article-title":"Effects of simvastatin and pravastatin on hyperlipidemia and cyclosporin blood levels in renal transplant recipients","volume":"19","author":"Capone","year":"1999","journal-title":"American Journal of Nephrology"},{"issue":"10","key":"10.1002\/14651858.CD005019.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1093\/ndt\/12.10.2140","article-title":"Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil","volume":"12","author":"Castro","year":"1997","journal-title":"Nephrology Dialysis Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0107|cit107","unstructured":"Cheng IKP Li PWC Janus ED Tang CSO Chan TM Lo CY Comparative efficacy of gemfibrozil (G) and simvastatin (S) in the treatment of hyperlipidaemia in renal transplant recipients (RT) - a randomised prospective study [abstract] ISN XIII International Congress of Nephrology; 1995 Jul 2-6; Madrid (Spain) 1995 383"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/ki.1982.130","article-title":"Effect of alternate-day prednisone on plasma lipids in renal transplant recipients","volume":"22","author":"Curtis","year":"1982","journal-title":"Kidney International"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00467-009-1128-7","article-title":"Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders","volume":"24","author":"Garcia-de-la-Puente","year":"2009","journal-title":"Pediatric Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0111|cit110","first-page":"1040","article-title":"Effect of diet, exercise and HMG-CoA reductase on hypercholesterolaemia in renal transplant patients [abstract]","volume":"8","author":"Gonzalez-Molina","year":"1993","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0110|cit111","first-page":"359","article-title":"Hyperlipoproteinemia in renal transplant patients: Effect of hypocaloric diet, exercise and HMG-CoA reductase inhibition","volume":"16","author":"Gonzalez-Molina","year":"1996","journal-title":"Nefrologia"},{"issue":"8847","key":"10.1002\/14651858.CD005019.pub4-BIB0113|cit112","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0140-6736(93)90546-S","article-title":"Cyclosporin and serum lipids in renal transplant recipients","volume":"341","author":"Hilbrands","year":"1993","journal-title":"Lancet"},{"issue":"12","key":"10.1002\/14651858.CD005019.pub4-BIB0112|cit113","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.V5122073","article-title":"The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients","volume":"5","author":"Hilbrands","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0021-9150(01)00438-5","article-title":"Changes in lipid metabolism and effect of simvastatin in renal transplant recipients induced by cyclosporine or tacrolimus","volume":"158","author":"Ichimaru","year":"2001","journal-title":"Atherosclerosis"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1399-0012.2005.00341.x","article-title":"Long term efficacy of simvastatin in renal transplant recipients treated with cyclosporine or tacrolimus","volume":"19","author":"Imamura","year":"2005","journal-title":"Clinical Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0116|cit116","first-page":"880A","article-title":"The effect of sirolimus on lipids on renal transplant recipients: results from clinical trials [abstract]","volume":"12","author":"Campistol","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005019.pub4-BIB0117|cit117","first-page":"185","article-title":"Statin therapy in renal transplant patients receiving everolimus: screening for clinical and pharmacokinetic drug interactions [abstract no:187]","volume":"2","author":"Kovarik","year":"2002","journal-title":"American Journal of Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/00007890-199001000-00021","article-title":"Lovastatin treatment of hypercholesterolemia in renal transplant recipients","volume":"49","author":"Kasiske","year":"1990","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0119|cit119","first-page":"3126","article-title":"Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine","volume":"28","author":"Kliem","year":"1996","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0272-6386(95)90133-7","article-title":"Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial","volume":"25","author":"Lal","year":"1995","journal-title":"American Journal of Kidney Diseases"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0121|cit121","first-page":"946","article-title":"Long term lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no:76P]","volume":"4","author":"Lal","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0122|cit122","first-page":"1100","article-title":"Three year follow up data on the lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract no: 372]","volume":"6","author":"Lal","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0123|cit123","first-page":"866","article-title":"Lipid lowering effects of nicotinic acid and lovastatin in renal transplant patients [abstract]","volume":"3","author":"Lal","year":"1992","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0124|cit124","first-page":"1915","article-title":"Lipid lowering effects of gemfibrozil and pravastatin with or without cholestyramine in diabetic renal transplant patients [abstract no: A3342]","volume":"7","author":"Lal","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0125|cit125","first-page":"683A","article-title":"Lipid lowering effects of niacin and lovastatin given alone or with cholestyramine in renal transplant patients [abstract]","volume":"9","author":"Lal","year":"1998","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005019.pub4-BIB0126|cit126","first-page":"A134","article-title":"The impact of aggressive cardiovascular risk modification on carotid intima media thickness and brachial artery reactivity in renal transplant recipients [abstract no: 132]","volume":"13","author":"Kaisar","year":"2008","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2369-10-29","article-title":"Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study","volume":"10","author":"Kaisar","year":"2009","journal-title":"BMC Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1159\/000097355","article-title":"Effects of pravastatin treatment on blood pressure regulation after renal transplantation","volume":"29","author":"Lopau","year":"2006","journal-title":"Kidney & Blood Pressure Research"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0129|cit129","first-page":"1103","article-title":"Effect of hypercholesterolemia and lipid-lowering therapy on glomerular filtration rate in renal transplants [abstract no: 1808]","volume":"6","author":"Markell","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.transproceed.2009.01.043","article-title":"A prudent algorithm for hyperlipoproteinemia in renal transplant recipients","volume":"41","author":"Nart","year":"2009","journal-title":"Transplantation Proceedings"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD005019.pub4-BIB0131|cit131","first-page":"952","article-title":"A prospective cross over trial to compare the efficacy and safety of lovastatin and gemfibrozil in the treatment of hyperlipidemic organ transplant recipients [abstract no: 76P]","volume":"4","author":"Nicholson","year":"1993","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1159\/000189121","article-title":"Further evidence of favorable effects of gemfibrozil on the lipid profile in renal allograft recipients","volume":"73","author":"Ok","year":"1996","journal-title":"Nephron"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0133|cit133","first-page":"1061","article-title":"Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]","volume":"6","author":"Olbricht","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0009-9236(97)90034-5","article-title":"Accumulation of lovastatin, but not pravastatin, in the blood of cyclosporine-treated kidney graft patients after multiple doses","volume":"62","author":"Olbricht","year":"1997","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0135|cit135","first-page":"1920","article-title":"Interaction of cyclosporine and fluvastatin with and without niacin in renal transplant patients with dyslipoproteinemia [abstract no: A3368]","volume":"7","author":"Raiola","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0136|cit136","unstructured":"Renders L Cardiovascular events in renal Transplant recipients with low LDL-cholesterol receiving tacrolimus in combination with the statin fluvastatin [CRANOC] www.clinicaltrials.gov\/ct2\/show\/NCT00223041"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1016\/S0041-1345(97)00521-6","article-title":"Cholesterol reduction in cyclosporine-treated renal transplant patients: effect on platelet-derived growth factor levels and platelet activation","volume":"29","author":"Rigatto","year":"1997","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0138|cit138","first-page":"49","article-title":"Treatment of hyperlipidemia after renal transplantation: Comparative effect of lovastatin and omega-3 fatty acids","volume":"17","author":"Rodriguez","year":"1997","journal-title":"Nefrologia"},{"issue":"8","key":"10.1002\/14651858.CD005019.pub4-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1016\/j.transproceed.2006.08.083","article-title":"Effect of statin treatment on oxidative stress and renal function in renal transplantation","volume":"38","author":"Ruiz","year":"2006","journal-title":"Transplantation Proceedings"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1023\/A:1015052312866","article-title":"The effect of fluvastatin of hyperlipidemia in renal transplant recipients: a prospective, placebo-controlled study","volume":"32","author":"Turk","year":"2001","journal-title":"International Urology & Nephrology"},{"issue":"2 Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00007890-200407271-00779","article-title":"Simvastatin for prevention of bone loss following renal transplantation [abstract no: P284]","volume":"78","author":"Vasquez","year":"2004","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0142|cit142","unstructured":"White M Hanes D Wiland A Klassen D Hoen-Saric E Schweitzer E Long-term treatment of hyperlipidemia in transplant recipients with pravastatin and gemfibrozil [abstract] 15th Annual Meeting American Society of Transplant Physicians (ASTP);1996 May 10-14; Chicago (ILL) 1996"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/01.tp.0000235446.50715.ef","article-title":"Effect of atorvastatin therapy and conversion to tacrolimus on hypercholesterolemia and endothelial dysfunction after renal transplantation","volume":"82","author":"Wissing","year":"2006","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0144|cit144","unstructured":"NCT00565474 Evaluation of the effect of fluvastatin 40 mg (b.i.d.) in the prevention of the development of vasculopathy of the graft in de novo renal transplant patients transplant www.clinicaltrials.gov\/ct2\/show\/NCT00565474"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/BF02564867","article-title":"Cardiovascular risk factors and diseases after renal transplantation","volume":"30","author":"Aker","year":"1998","journal-title":"International Urology & Nephrology"},{"issue":"23","key":"10.1002\/14651858.CD005019.pub4-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"2998","DOI":"10.1001\/jama.288.23.2998","article-title":"Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)","volume":"288","author":"ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial","year":"2002","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0148|cit148","unstructured":"Australia New Zealand Dialysis Transplant Registry (ANZDATA) The 33rd Annual Report 2010 http:\/\/www.anzdata.org.au\/v1\/report_2010.html"},{"issue":"9493","key":"10.1002\/14651858.CD005019.pub4-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"issue":"17","key":"10.1002\/14651858.CD005019.pub4-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1001\/jama.295.17.2046","article-title":"Effects of early treatment with statins on short-term clinical outcomes in acute coronary syndromes: a meta-analysis of randomized controlled trials","volume":"295","author":"Briel","year":"2006","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/S0041-1345(98)00246-2","article-title":"Lipoprotein patterns in renal transplant patients: a comparison between FK506 and cyclosporine A patients","volume":"30","author":"Claesson","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0021-9150(93)90107-6","article-title":"Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase","volume":"10","author":"Corsini","year":"1993","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1053\/ajkd.2002.34927","article-title":"Patient survival after renal transplantation III: the effects of statins","volume":"40","author":"Cosio","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"9753","key":"10.1002\/14651858.CD005019.pub4-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD005019.pub4-BIB0155|cit155","first-page":"iii67","article-title":"The effects of hyperlipidaemia on graft and patient outcome in renal transplantation","volume":"19","author":"Castillo","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD005019.pub4-BIB0156|cit156","first-page":"26","article-title":"European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.5.3. Cardiovascular risks. Hyperlipidaemia","volume":"17","author":"EBPG Expert Group on Renal Transplantation","year":"2002","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1111\/j.1523-1755.2004.00919.x","article-title":"Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial","volume":"66","author":"Fellstr\u00f6m","year":"2004","journal-title":"Kidney International"},{"issue":"8","key":"10.1002\/14651858.CD005019.pub4-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"issue":"7","key":"10.1002\/14651858.CD005019.pub4-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"issue":"7650","key":"10.1002\/14651858.CD005019.pub4-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"20","key":"10.1002\/14651858.CD005019.pub4-BIB0161|cit161","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Statistics in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD005019.pub4-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1681\/ASN.V5122073","article-title":"The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients","volume":"5","author":"Hilbrands","year":"1995","journal-title":"Journal of the American Society of Nephrology"},{"issue":"9374","key":"10.1002\/14651858.CD005019.pub4-BIB0163|cit163","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007890-199401000-00013","article-title":"Risk factors predicting chronic rejection of renal allografts","volume":"57","author":"Isoniemi","year":"1994","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S0140-6736(11)61334-2","article-title":"Prevention of cardiovascular disease in adult recipients of kidney transplants","volume":"15","author":"Jardine","year":"2011","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0166|cit166","first-page":"14","article-title":"The effect of cyclosporine A on plasma lipids during the first year after transplantation","volume":"12","author":"John","year":"1999","journal-title":"National Medical Journal of India"},{"issue":"21","key":"10.1002\/14651858.CD005019.pub4-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":"Cardiovascular disease after renal transplantation","volume":"7","author":"Kasiske","year":"1996","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 7","key":"10.1002\/14651858.CD005019.pub4-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"American Journal of Transplantation"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1600-6143.2009.02834.x","article-title":"KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group","year":"2009","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/0162-3109(96)00108-7","article-title":"Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro","volume":"34","author":"Kurakata","year":"1996","journal-title":"Immunopharmacology"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1093\/ndt\/gfh385","article-title":"Statin use after renal transplantation: a systematic quality review of trial-based evidence","volume":"19","author":"Lentine","year":"2004","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0173|cit173","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1681\/ASN.2004070580","article-title":"Incidence and predictors of myocardial infarction after kidney transplantation","volume":"16","author":"Lentine","year":"2005","journal-title":"Journal of the American Society of Nephrology : JASN"},{"issue":"8994","key":"10.1002\/14651858.CD005019.pub4-BIB0174|cit174","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S0140-6736(96)90217-2","article-title":"Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction?","volume":"347","author":"Massy","year":"1996","journal-title":"Lancet"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD005019.pub4-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1097\/00007890-200109271-00005","article-title":"Hyperlipidemia and cardiovascular disease after organ transplantation","volume":"72","author":"Massy","year":"2001","journal-title":"Transplantation"},{"issue":"6","key":"10.1002\/14651858.CD005019.pub4-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/ajhp\/61.6.565","article-title":"Drug-related dyslipidemia after renal transplantation","volume":"61","author":"Mathis","year":"2004","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"5","key":"10.1002\/14651858.CD005019.pub4-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.transproceed.2004.05.036","article-title":"Metaanalysis of statins and survival in de novo cardiac transplantation","volume":"36","author":"Mehra","year":"2004","journal-title":"Transplantation Proceedings"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0178|cit178","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007784","article-title":"HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0179|cit179","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease evaluation, classification and stratification","volume":"39","author":"National Kidney Foundation","year":"2002","journal-title":"American Journal of Kidney Diseases"},{"issue":"9","key":"10.1002\/14651858.CD005019.pub4-BIB0180|cit180","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004289.pub5","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients","author":"Palmer","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/oxfordjournals.ndt.a091698","article-title":"Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients","volume":"3","author":"Raine","year":"1988","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD005019.pub4-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007890-199802150-00030","article-title":"Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine","volume":"65","author":"Satterthwaite","year":"1998","journal-title":"Transplantation"},{"issue":"9364","key":"10.1002\/14651858.CD005019.pub4-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","article-title":"Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0184|cit184","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"issue":"20","key":"10.1002\/14651858.CD005019.pub4-BIB0185|cit185","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolaemia. West of Scotland Coronary Prevention Study","volume":"333","author":"Shepherd","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD005019.pub4-BIB0186|cit186","unstructured":"USRDS USRDS 2011 Annual Data Report. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD http:\/\/www.usrds.org\/2011\/pdf\/v2_ch04_11.pdf 2011 14655174"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0187|cit187","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00007890-198907000-00009","article-title":"Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients","volume":"48","author":"Vathsala","year":"1989","journal-title":"Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD005019.pub4-BIB0188|cit188","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019.pub2","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD005019.pub4-BIB0189|cit189","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019.pub3","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant recipients","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD005019.pub4-BIB0190|cit190","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005019","article-title":"HMG CoA reductase inhibitors (statins) for kidney transplant patients","author":"Perkovic","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD005019.pub4\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T09:49:46Z","timestamp":1704448186000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD005019.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,1,27]]},"references-count":190,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd005019.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,27]]}}}